상세정보
Export to Refworks부가기능
From breakthrough to blockbuster the business of biotechnology
상세 프로파일
| 자료유형 | 단행본 |
|---|---|
| 서명/저자사항 | From breakthrough to blockbuster : the business of biotechnology/ Donald L. Drakeman, Lisa N. Drakeman, Nektarios Oraiopoulos. |
| 개인저자 | Drakeman, Donald L.,author. Drakeman, Lisa Natale,author, Oraiopoulos, Nektarios,author, |
| 형태사항 | 1 online resource (1 volume): illustrations. |
| 기타형태 저록 | Print version: Drakeman, Donald L. From breakthrough to blockbuster New York, NY : Oxford University Press, 2022 9780195084009 |
| ISBN | 9780197626313 0197626319 0197626300 9780197626306 |
| 서지주기 | Includes bibliographical references and index. |
| 요약 | "Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"-- |
| 해제 | Provided by publisher. |
| 일반주제명 | Biotechnology industries. Bio-industries. Biotechnology industries. |
| 언어 | 영어 |
| 바로가기 |  |
